Even patients with low fracture risk benefit from bisphosphonates, NICE says

Osteoporosis patients with a risk of fracture above 1% could benefit from bisphosphonates, NICE has said, but charities have called for GPs to be given more guidance on prescribing.

Bisphosphonates are cost effective even in people with very low risk of fracture, NICE has concluded in its latest technology appraisal.

Oral bisphosphonates should be considered to treat osteoporosis in adults with a 10-year probability of related fracture as low as 1% – as according to the FRAX or QFracture risk tools, it said.

Intravenous bisphosphonates are recommended if risk of fracture is above 10%, or if a patient with a risk over 1% cannot take or tolerate the oral version.

It adds that the choice of treatment should be made on an individual basis after a discussion between the responsible clinician and the patient.

Bisphosphonates – including alendronic acid, risedronate, ibandronate and zoledronic acid – are the most common group of drugs used to treat osteoporosis.

Fracture risk

The revamped recommendations apply to men as well as women, and come in light of a new meta-analysis confirming that bisphosphonates are more effective at reducing the risk of fracture compared to placebo.

The National Osteoporosis Society warned GPs that – although the drugs are clinically and cost effective – they may not be appropriate for every patient with a low fracture risk.

‘There is a risk that if the [technology appraisal] is not correctly applied people could receive a treatment when they don’t need one,’ it said.

‘With growing concerns about possible rare long-term effects of bisphosphonate treatments, we want to make sure that people are only given a treatment when the benefits of treatment outweigh the risks.

‘Health professionals, especially non-specialists like GPs, may need some additional guidance to support their decisions about which patients should be offered a bisphosphonate.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

England's £20,000 golden hello scheme could poach GP partners from other UK countries

England's £20,000 golden hello scheme could poach GP partners from other UK countries

GPs partners in Wales, Scotland and Northern Ireland could be poached by the English...

Viewpoint: How GPs can build a more equal post-COVID world through health creation

Viewpoint: How GPs can build a more equal post-COVID world through health creation

Former NHS chief executive Lord Nigel Crisp explains why the UK needs to focus on...

Mandatory face covering in GP practices vital as face-to-face contacts rise, warns BMA

Mandatory face covering in GP practices vital as face-to-face contacts rise, warns BMA

Face coverings should be mandatory for patients visiting GP practices amid a rapid...

Workshops to help overseas doctors adapt to NHS go online as GMC reacts to pandemic

Workshops to help overseas doctors adapt to NHS go online as GMC reacts to pandemic

Free GMC workshops to help overseas doctors adjust to working in the UK are being...

How new technology can help GPs manage ENT patients

How new technology can help GPs manage ENT patients

Dr Marcelino Ruiz-Martin and Dr Ruth Chambers explain how a practice in Staffordshire...

Face-to-face GP consultations up 70% since start of lockdown

Face-to-face GP consultations up 70% since start of lockdown

Face-to-face GP consultations have risen 70% compared with the early stages of lockdown,...